One of the largest global healthcare challenges of the 21st century is improving access to adequate diagnostic testing, as emphasized by the SARS-COV-2 pandemic beginning in 2019. This is especially true in limited-resource settings where they lack the traditional healthcare infrastructure that is often necessary for rapid and accurate diagnosis, leaving countless patients undiagnosed and without proper treatment. Nucleic acid testing (NAT) is a molecular approach that can be used to diagnose a variety of pathogenic and genetic diseases through DNA quantification of a specific target, such as viral DNA, within a patient sample. Point-of-care (POC) application of NAT technologies can have powerful impacts globally, but perhaps most significantly in limited-resource settings where deployment of novel devices and methods in a decentralized setting can potentially out-pace the development of traditional healthcare infrastructure.This dissertation details the development of three unique technologies to improve access to rapid and accurate diagnosis through NAT at the point-of-care. The second chapter describes a novel approach to diagnose a viral-borne skin cancer – Kaposi’s sarcoma (KS) – using a POC device, TINY. The third chapter describes an extension of our goal for accessible NAT testing as we describe the development of a high-throughput device for COVID-19 testing, capable of hundreds of samples per day. The fourth chapter will discuss a novel POC device for the rapid extraction of DNA from skin tissue biopsies, further enhancing the POC impact of molecular KS-diagnosis described in the second chapter. All three chapters detail developments for enabling rapid and accurate nucleic acid diagnosis, especially in limited-resource settings, through novel devices and techniques that can be applied at the point-of-care.